Tan Jiaying, Yu Wenjin, Wu Gang, Shen Jun, Fang Yong, Zhu Hechen, Xiao Qianyi, Peng Weixia, Lan Yukun, Gong Ye
Department of Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai 200040, People's Republic of China.
Department of Pharmacy , Huashan Hospital, Fudan University, Shanghai 200040, People's Republic of China.
Infect Drug Resist. 2020 Jul 21;13:2453-2463. doi: 10.2147/IDR.S247378. eCollection 2020.
We conducted a real-world analysis of the effectiveness of different antibiotic regimens for bloodstream infections (BSIs) caused by carbapenem-resistant gram-negative bacilli (CR-GNB) in a Chinese population.
A retrospective observational study was conducted between January 2010 and December 2017. Patients with BSIs caused by CR-GNB confirmed by in vitro susceptibility tests were enrolled, and patient medical record data on antimicrobial agents and microbiological and clinical outcomes were extracted.
A total of 175 individuals were included; 127 individuals (72.6%) received combination therapy (two or more antibiotics), while 48 individuals (27.4%) received monotherapy (single antibiotic). The all-cause 28-day mortality was 20.0%. Treatment success or presumed success rates were very similar between the monotherapy and combination therapy groups (58.3% versus 59.1%; P = 0.931). Combination therapy had a higher success rate trend than monotherapy in septic shock patients (40.7% versus 18.2%; P = 0.268). Improved therapeutic effects were observed in the active agent-containing group, although the differences were not significant.
Combination therapy likely has better therapeutic effects on critical BSIs caused by CR-GNB than monotherapy. Choosing a proper active agent in an antimicrobial regime is relatively crucial to the ultimate treatment outcome.
我们对不同抗生素方案治疗中国人群中耐碳青霉烯类革兰阴性杆菌(CR-GNB)引起的血流感染(BSIs)的有效性进行了一项真实世界分析。
在2010年1月至2017年12月期间进行了一项回顾性观察研究。纳入经体外药敏试验确诊为CR-GNB引起的BSIs患者,并提取患者关于抗菌药物以及微生物学和临床结局的病历数据。
共纳入175例个体;127例个体(72.6%)接受联合治疗(两种或更多种抗生素),而48例个体(27.4%)接受单药治疗(单一抗生素)。全因28天死亡率为20.0%。单药治疗组和联合治疗组的治疗成功或推测成功率非常相似(58.3%对59.1%;P = 0.931)。在感染性休克患者中,联合治疗的成功率趋势高于单药治疗(40.7%对18.2%;P = 0.268)。在含有效抗菌药物组中观察到治疗效果有所改善,尽管差异不显著。
对于CR-GNB引起的严重BSIs,联合治疗可能比单药治疗具有更好的治疗效果。在抗菌治疗方案中选择合适的有效抗菌药物对最终治疗结局相对至关重要。